Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05162833 · ClinicalTrials.gov registry record · NA
Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
A NA study, sponsored by Theranova, L.L.C..
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT05162833 is a NA study that has completed, run by Theranova, L.L.C.. The registered enrollment target is 3 participants.
The verdict
NCT05162833, a NA study, has completed, sponsored by Theranova, L.L.C..
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
To evaluate the safety and durability of the TheraNova Neuromodulation System in overactive bladder (OAB) patients.
Interventions
- DEVICE TheraNova Neuromodulation Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-02-20 |
| Est. Completion | 2023-12-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05162833
The ClinicalTrials.gov registry entry for NCT05162833 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranova, L.L.C., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TheraNova Neuromodulation Device is the first listed.
NCT05162833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05162833 about?
NCT05162833 is a clinical study titled "Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms". To evaluate the safety and durability of the TheraNova Neuromodulation System in overactive bladder (OAB) patients.
What is the current status of trial NCT05162833?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2022-02-20. Estimated completion is 2023-12-08.
What interventions are being tested in trial NCT05162833?
The interventions under investigation include: TheraNova Neuromodulation Device (DEVICE).
Who is sponsoring clinical trial NCT05162833?
This trial is sponsored by Theranova, L.L.C., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.